CN114010563A - Component with brightening and anti-aging effects and application thereof - Google Patents
Component with brightening and anti-aging effects and application thereof Download PDFInfo
- Publication number
- CN114010563A CN114010563A CN202111439984.XA CN202111439984A CN114010563A CN 114010563 A CN114010563 A CN 114010563A CN 202111439984 A CN202111439984 A CN 202111439984A CN 114010563 A CN114010563 A CN 114010563A
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- skin
- promoting
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0629—Keratinocytes; Whole skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
Abstract
The invention discloses a component with brightening and anti-aging effects and application thereof, wherein the component is a peony root extract.
Description
Technical Field
The invention relates to the field of daily chemical industry, in particular to application of a peony root extract as a component with brightening and anti-aging effects.
Background
Skin aging occurs in both the epidermis and dermis layers. Collagen synthesis in the dermis decreases with age, and environmental stresses such as uv light also accelerate collagen degradation. Therefore, the method has wide consensus in the field of skin aging resistance, and has the advantages of improving the collagen synthesis capacity of fibroblasts in the dermis and protecting collagen from being damaged. The outermost layer of the epidermis is the stratum corneum. The stratum corneum generally consists of 10-20 layers of flat, anucleate keratinocytes, which are connected by keratomes; with the disruption of the cuticle, the keratinocytes are exfoliated and the keratinocytes below the epidermis are moved up to form a new stratum corneum, a process of epidermal renewal. With age, the stratum corneum of the skin thickens, which leads to old waste keratin deposits and dull skin tone. Chemical exfoliation is the exfoliation of superficial cells of the skin by organic acid components, thereby accelerating the renewal of the skin and improving dullness and photoaging of the skin. However, these exfoliative ingredients also tend to cause skin irritation and require professional manipulation. However, the skin itself has the ability to regulate metabolism and turnover. Members of the kallikrein-related peptidases (KLK) family in skin, such as KLK5 and KLK7, have been found to degrade keratinocytes, thereby regulating keratinocyte exfoliation and epidermal layer turnover.
In the prior art, extract of Hibiscus alpinus Leontopodium (Majestrem) of SedermaTM) Can promote the synthesis of new collagen; palmitoyl tripeptide of DSM-5 (
Coll) can both protect collagen and promote the synthesis of new collagen. Fruit acids, salicylic acid and glycolic acid promote epidermal turnover, but are also prone to irritation.
Therefore, there is a need in the art to provide a milder component for deactivating the metabolic turnover process of the epidermis itself, and simultaneously promoting the production of collagen in the dermis, so as to achieve the purpose of synergistically brightening the dermis and epidermis and resisting aging.
Disclosure of Invention
The invention aims to provide a method for synergistically brightening and resisting aging on a dermis layer and an epidermis layer.
In a first aspect of the present invention, there is provided a use of an extract of paeonia lactiflora pall in preparing a composition for promoting exfoliation of the stratum corneum of skin.
In another embodiment, said promoting exfoliation of the stratum corneum layer of the skin comprises promoting expression of KLK5 and/or KLK7 in keratinocytes.
In another embodiment, the composition comprises 0.01-100 wt% of the extract of paeonia lactiflora pall, based on the total weight of the composition.
In another embodiment, the composition is a dermatological product.
In another embodiment, the composition comprises an extract of paeonia lactiflora pall and a cosmetically acceptable carrier.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of the peony root extract is 0.001-5 wt% based on the total weight of the composition.
In a second aspect of the present invention, there is provided a use of an extract of paeonia lactiflora pall in the preparation of a composition for promoting the renewal of the epidermal layer of skin.
In another embodiment, the promoting renewal of the epidermal layer of skin comprises promoting expression of KLK5 and/or KLK7 in keratinocytes.
In another embodiment, the composition comprises 0.01-100 wt% of the extract of paeonia lactiflora pall, based on the total weight of the composition.
In another embodiment, the composition is a dermatological product.
In another embodiment, the composition comprises an extract of paeonia lactiflora pall and a cosmetically acceptable carrier.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of the peony root extract is 0.001-5 wt% based on the total weight of the composition.
In a third aspect of the present invention, there is provided a use of an extract of paeonia lactiflora pall in preparing a composition for anti-skin aging.
In another embodiment, the anti-skin aging comprises improving aging of the dermal layer.
In another embodiment, the anti-skin aging comprises promoting collagen production in the dermal layer of the skin.
In another embodiment, the improving aging of the dermal layer comprises promoting collagen i production in fibroblasts of the dermal layer.
In another embodiment, the composition comprises 0.01-100 wt% of the extract of paeonia lactiflora pall, based on the total weight of the composition.
In another embodiment, the collagen is type i collagen.
In another embodiment, the composition is a dermatological product.
In another embodiment, the composition comprises an extract of paeonia lactiflora pall and a cosmetically acceptable carrier.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of the peony root extract is 0.001-5 wt% based on the total weight of the composition.
In a fourth aspect of the present invention, there is provided a use of an extract of paeonia lactiflora pall for preparing a composition for anti-aging and/or promoting skin renewal.
In another embodiment, the composition comprises 0.01-100 wt% of the extract of paeonia lactiflora pall, based on the total weight of the composition.
In another embodiment, the composition is a dermatological product.
In another embodiment, the composition comprises an extract of paeonia lactiflora pall and a cosmetically acceptable carrier.
In another embodiment, the product form is selected from a solution, gel, cream, liniment, microemulsion spray, suspension or emulsion.
In another embodiment, the concentration of the peony root extract is 0.001-5 wt% based on the total weight of the composition.
In a fifth aspect of the invention, there is provided a method for promoting expression of KLK5 and/or KLK7 in keratinocytes in vitro, the method comprising the steps of: mixing keratinocyte with radix Paeoniae extract.
In a sixth aspect of the present invention, there is provided a method for promoting collagen i production in dermal fibroblasts in vitro, the method comprising the steps of: mixing fibroblast with radix Paeoniae extract.
Accordingly, the invention provides a milder component for deactivating the metabolism renewal process of the epidermis, and simultaneously promoting the generation of collagen in the dermis, so as to finally achieve the purpose of synergetic brightening and anti-aging in the dermis and the epidermis.
Drawings
FIG. 1 shows that the peony root extract of example 1 promotes PCR amplification of KLK5 and KLK 7.
FIG. 2 shows the condition of the peony root extract in example 2 promoting the synthesis of collagen I on fibroblasts.
Detailed Description
The inventor unexpectedly finds that the paeonia lactiflora root extract can promote the expression of KLK5 and KLK7 in keratinocytes and can also promote the generation of protein I in fibroblasts of a dermis layer, so that the paeonia lactiflora root extract can play the effects of resisting skin aging and stimulating skin renewal. On the basis of this, the present invention has been completed.
As used herein, "peony root extract" refers to a mixture rich in paeoniflorin, wherein the content of paeoniflorin is not less than 45% by weight of the total weight of the mixture. Paeoniflorin is a glycosylated monoterpene, and the chemical structure is shown as formula I:
as used herein, "keratinocytes (keratinocytes)" also known as keratinocytes or keratin-forming cells, are the major cellular components that make up the epidermal layer. Keratinocytes at different differentiation stages form the four-layer structure of the epidermal layer of the skin, which is the stratum corneum, the stratum granulosum, the stratum spinosum and the stratum basale from the outside to the inside. The epidermal layer of keratinocytes serves a barrier function.
As used herein, "keratolysis" refers to the exfoliation of keratinocytes caused by the disruption of the corneoplast between the keratinocytes. Exfoliation of the stratum corneum causes keratinocytes below the epidermis to move up to form a new stratum corneum, thereby achieving renewal of the epidermis.
As used herein, "dermal layer" refers to one of the three layers of skin, between the epidermal layer and the subcutaneous tissue. The extracellular matrix of the dermis contains a large amount of polysaccharide and protein, the protein is mainly composed of collagen and elastin (elastin), and the other is composed of tissues such as nerves, capillaries, sweat glands, sebaceous glands, lymphatic vessels, hair roots and the like. Among the cells in the normal dermis are fibroblasts, macrophages, and mast cells.
As used herein, "collagen I" or "type I collagen" are used interchangeably and refer to collagen that is located in the dermis to provide a support structure, provide elasticity, and the like.
In this context, "fibroblasts" are the major cellular components of loose connective tissue, the most prominent cell type of the dermis, with cells in the shape of fusiform or flat stars with protrusions.
The term "effective amount" is intended to mean an amount which, after a suitable period of use, is capable of promoting and assisting the expression of KLK5 and/or KLK7 in keratinocytes and/or of promoting and assisting the synthesis of fibrinogen protein in fibroblasts of the dermis for the purpose of improving epidermal and/or dermal senescence.
"composition" refers to a composition that, when applied to an individual (typically a human), is capable of penetrating the skin to induce the desired effects of promoting the exfoliation of the stratum corneum, the renewal of the epidermis and/or the production of collagen in the dermis of the skin.
As used herein, the term "cosmetically acceptable carrier" refers to a carrier that allows a cosmetic or personal care product to be applied, including various excipients and diluents, which are not themselves essential active ingredients, and which do not have undue toxicity after application. Suitable carriers are well known to those of ordinary skill in the art. A sufficient discussion of cosmetically acceptable excipients can be found in the cosmetic hygiene specifications 2015 edition. Such carriers may include humectants, emulsifiers, thickeners, chelating agents, emollients, and the like in the composition. Such as, but not limited to, water, potassium hydroxide, 1, 2-hexanediol, p-hydroxyacetophenone, methylparaben, phenoxyethanol, ethylhexyl glycerol, butylene glycol, panthenol, dipotassium glycyrrhizinate, arginine, glycerol, sodium hyaluronate, propylene glycol, hexylene glycol, glyceryl stearate/PEG-100 stearate, glyceryl caprylate, xanthan gum, betaine, hydroxyethyl cellulose, carbomer, disodium EDTA, isocetyl palmitate, isooctyl palmitate, ethylhexyl palmitate, cetostearyl alcohol, dimethicone, citric acid or a salt thereof, behenyl alcohol polyether, ceteth alcohol, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl alcohol ethylhexanoate, and the like.
The term "administering" as used herein means directly administering an equivalent amount of the extract of paeonia lactiflora pall.
The terms "individual" or "individual" are used herein to refer to a person who can receive the paeonia lactiflora extract and/or method for application to the skin.
As used herein, "room temperature" means 15-45 deg.C, preferably 20-35 deg.C.
The present invention provides a method of promoting exfoliation of the stratum corneum layer of skin and/or promoting turnover of the epidermis layer of skin comprising promoting expression of KLK5 and/or KLK7 in keratinocytes. The method comprises administering an extract of radix Paeoniae. The concentration of the radix Paeoniae extract is 0.01-3.0mg/mL, such as but not limited to 0.01-0.5mg/mL, 0.02-0.7mg/mL, 0.3-2.0mg/mL, 0.05-1.5mg/mL, etc., if the radix Paeoniae extract is liquid.
In one embodiment of the present invention, the peony root extract administered is the only active ingredient.
In one embodiment of the present invention, the paeonia lactiflora pall extract is obtained from Shanghai jin Cheng chemical Co., Ltd
The substance of PL.
The invention provides a method for promoting the generation of collagen in the dermis layer of skin, which comprises promoting the synthesis of collagen I on fibroblasts. The method comprises administering an extract of radix Paeoniae. The concentration of the radix Paeoniae extract is 0.01-3.0mg/mL, such as but not limited to 0.01-0.5mg/mL, 0.02-0.7mg/mL, 0.3-2.0mg/mL, 0.05-1.5mg/mL, etc., if the radix Paeoniae extract is liquid.
In one embodiment of the present invention, the peony root extract administered is the only active ingredient.
In the present inventionIn one embodiment, the radix Paeoniae extract is obtained from Shanghai jin Cheng chemical Co., Ltd
The substance of PL.
Further, the present invention provides a composition comprising an extract of paeonia lactiflora pall and a cosmetically acceptable carrier, thereby obtaining various cosmetics or personal care products for application to human skin, including, but not limited to, a makeup cream, a sunscreen cream, a face cream, an eye cream, an emulsion, a essence, a lotion, a gel, etc. In one embodiment of the present invention, the peony root extract is the only active ingredient in the composition.
The present invention provides a cosmetic or personal care product comprising 0.001-5 wt% of an extract of peony root, such as, but not limited to, 0.01-0.03 wt%, 0.008-3 wt%, 0.05-0.7 wt%, 0.4-2.5 wt%, 0.1-1.4 wt%, 0.06-2 wt%, etc., based on the total weight of the product.
In some embodiments of the present invention, the cosmetic or personal care product is obtained by combining the compositions provided herein with a cosmetically acceptable carrier that can be used to form the aqueous phase. The cosmetically acceptable carrier that may be used to form the aqueous phase includes, but is not limited to, one or more of methylparaben, ethylhexylglycerin, butylene glycol, glycerin, sodium hyaluronate, and water.
In one embodiment of the present invention, the composition provided by the present invention is mixed with water to form an aqueous phase, and then mixed with a cosmetically acceptable carrier for the oil phase and emulsified to obtain the cosmetic or personal care product. Preferably, the cosmetic or personal care product may be formed by adding preservatives, perfumes, etc. after emulsification and cooling to room temperature.
In another embodiment of the present invention, the cosmetic or personal care product is obtained by adding the composition provided by the present invention after mixing and emulsifying the cosmetically acceptable carrier of the oil phase and the cosmetically acceptable carrier of the water phase. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after emulsification and cooling to room temperature.
In another embodiment of the invention, the cosmetic or personal care product may also be obtained by adding the composition provided by the present invention after homogenization of the aqueous cosmetically acceptable carrier. Preferably, the cosmetic or personal care product may be formed by adding the composition provided by the present invention after homogenization and cooling to room temperature.
In some embodiments of the invention, the cosmetically acceptable carrier used to form the oil phase includes, but is not limited to, one or more of glyceryl stearate, glyceryl monostearate, glyceryl stearate/PEG-100 stearate complex, isomeric hexadecanes, isooctyl palmitate, ethylhexyl palmitate, cetearyl alcohol, behenyl alcohol, cetostearyl alcohol, ceteth, dimethicone, pentaerythritol tetrakis (ethylhexanoate), squalane, cetyl ethylhexanoate petrolatum, shea butter, squalane, lecithin.
Although numerical ranges and parameters setting forth the broad scope of the invention are approximate, the values set forth in the specific examples are presented as precisely as possible. Any numerical value, however, inherently contains certain standard deviations found in their respective testing measurements. As used herein, "about" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "about" means that the actual value falls within the acceptable standard error of the mean, as considered by those skilled in the art. Except in the experimental examples, or where otherwise expressly indicated, it is to be understood that all ranges, amounts, values and percentages herein used (e.g., to describe amounts of materials, length of time, temperature, operating conditions, quantitative ratios, and the like) are to be modified by the word "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, these numerical parameters are to be understood as meaning the number of significant digits recited and the number resulting from applying ordinary carry notation.
Unless defined otherwise herein, the scientific and technical terms used herein have the same meaning as is commonly understood and used by one of ordinary skill in the art. Furthermore, as used herein, the singular tense of a noun, unless otherwise conflicting with context, encompasses the plural form of that noun; the use of plural nouns also covers the singular form of such nouns.
To make the features and effects of the present invention comprehensible to those skilled in the art, general description and definitions are made below with reference to terms and expressions mentioned in the specification and claims. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The theory or mechanism described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, i.e., the present disclosure may be practiced without limitation to any particular theory or mechanism.
All features defined herein as numerical ranges or percentage ranges, such as values, amounts, levels and concentrations, are for brevity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to cover and specifically disclose all possible subranges and individual numerical values (including integers and fractions) within the range.
The features mentioned above with reference to the invention, or the features mentioned with reference to the embodiments, can be combined arbitrarily. All features disclosed in this specification may be combined in any combination, provided that there is no conflict between such features and the combination, and all possible combinations are to be considered within the scope of the present specification. Each feature disclosed in this specification may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, the features disclosed are merely generic examples of equivalent or similar features.
The main advantages of the invention are: the composition provided by the invention can simultaneously act on epidermis rejuvenation and dermis collagen generation, and has the effects of brightening and anti-aging skin care.
The invention will be further illustrated with reference to the following specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. The experimental procedures, in which specific conditions are not noted in the following examples, are generally carried out according to conventional conditions or according to conditions recommended by the manufacturers. All percentages, ratios, proportions, or parts are by weight unless otherwise specified. The weight volume percentage units in the present invention are well known to those skilled in the art and refer to, for example, the weight of solute in a 100 ml solution. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In addition, any methods and materials similar or equivalent to those described herein can be used in the methods of the present invention. The preferred embodiments and materials described herein are intended to be exemplary only.
Example 1
Paeonia lactiflora root extract for promoting expression of KLK5 and KLK7 in keratinocytes
Material
The test system comprises:
the cells used in this test were keratinocytes, lot No.: EP21012001, obtained by cell primary, subculture, Guangdong Boxi Biotech limited.
The main reagents are as follows:
KC2500 broth (guangdong boxi), mtt (sigma), dmso (sigma), PBS (bosch de), rnaioso Plus (Takara), reverse transcription kit (Takara), fluorescent dye (Takara).
The main equipment is as follows:
CO2incubator (Thermo), clean bench (Sujing Antai), inverted microscope (Olympus), micro-oscillator (Linbel), enzyme labeling instrument (BioTek), incubator (Tester), fluorescent quantitative PCR instrument (BioRad), general PCR instrument (Bori).
Paeonia lactiflora root extract is purchased from Shanghai Jincheng chemical Co., Ltd, and has the trade name:
PL
Method
cell inoculation:
by 2.8X 105The cells were seeded at a seeding density per well into 6-well plates and incubated overnight in an incubator (37 ℃, 5% CO 2).
Preparing liquid:
control group: PBS (phosphate buffered saline, containing no active substance)
Sample set 1: radix Paeoniae extract dissolved in PBS, wherein radix Paeoniae concentration is 1.3mg/mL
Sample set 2: radix Paeoniae extract dissolved in PBS, wherein radix Paeoniae concentration is 0.65mg/mL
Administration: according to the test scheme in Table 1, when the cell plating rate in the 6-well plate reaches 40% -60%, the administration amount is 2mL per well, each group is provided with 3 multiple wells, and the incubator (37 ℃, 5% CO)2) And (4) performing medium incubation for 24 h.
TABLE 1
Collecting a sample: after 24h incubation, the solution was discarded, washed twice with 1 mL/well PBS, 1mL of RNAioso Plus was added to each well, and the lysed cells were aspirated and collected.
And (3) gene expression detection: extracting RNA, carrying out reverse transcription to cDNA, carrying out fluorescent quantitative PCR detection, and calculating the result by adopting a 2-delta CT method.
And (4) result statistical analysis: and (3) mapping by using GraphPad Prism Program software, wherein the difference is obvious when p is less than 0.05 and extremely obvious when p is less than 0.01 by adopting t-test statistical analysis among groups.
Results
See figure 1.
The peony root extract significantly promoted the expression of KLK5(p <0.05) and KLK7(p <0.05) in keratinocytes at a dose of 0.65 mg/mL; the expression of KLK5(p <0.05) and KLK7(p <0.05) in keratinocytes was significantly promoted at a dose of 1.3 mg/mL.
The results show that the peony root extract has the effect of degrading keratin, thereby promoting the exfoliation of the horny layer and the renewal of the epidermal layer.
Example 2
Paeonia lactiflora root extract for promoting collagen I generation in dermal fibroblast
Material
Test cells:
the cells used in this experiment were human dermal fibroblasts, purchased from conlang organisms.
Experimental reagent:
DMEM high-glucose medium (Biosharp), fetal bovine serum (Biosharp), dpbs (Biosharp), mtt (Biosharp), dmso (Biosharp), 0.25% pancreatin (Biosharp).
Experimental equipment:
CO2incubator (Shanghai Boxun, BC-J160), biological safety cabinet (Shanghai Shang dao, BHC-1300IIA2), enzyme labeling instrument (TECAN, Infinite F50), and centrifuge (Hunan Xiang instrument, H1850R).
Paeonia lactiflora root extract is purchased from Shanghai Jincheng chemical Co., Ltd, and has the trade name:
PL TGF-. beta.1 from PeproTech
Experimental methods
Cell inoculation:
cells were seeded at 4000 cells/well in 96-well plates, 3 replicates per assay concentration, 37 ℃, 5% CO2The incubator is used for 24h +/-2.
Administration:
after 24h + -2, the medium in the 96-well plate was discarded, the medium containing the test substance was added to the test substance wells, and the medium containing the positive control was added to the positive control wells at 200. mu.L per well. After the administration, the 96-well plate was placed in CO2Culturing for 72h +/-2 h in an incubator.
The blank group of drugs is DPBS + DMEM medium
The drug of the positive control group is TGF-beta 1, and the growth factor is widely used for stimulating the generation of collagen in experiments; TGF-. beta.1 was dissolved in DPBS and added to DMEM
Dissolving radix Paeoniae extract in DPBS, and adding DMEM
Collecting a supernatant:
after the incubation culture is finished, 200. mu.L of cell culture supernatant is collected in each hole and placed in a 1.5mL sterile centrifuge tube, and the cell culture supernatant is frozen and stored in an ultra-low temperature refrigerator at minus 80 ℃.
The ELISA kit detects the content of the type I collagen:
ELISA detection needs to be carried out according to the use instruction of the human type I collagen ELISA kit. Statistical analysis was performed using the t-test method, and p-values <0.05 for the PC group and the sample group compared to the blank group indicated significant differences.
Results
See figure 2.
On fibroblasts, the peony root extract (0.8mg/mL) significantly promoted the synthesis of collagen I on fibroblasts (p < 0.05). The positive control TGF beta-1 (transforming growth factor-1) also significantly increased the synthesis of collagen I on fibroblasts (p < 0.05).
The results show that the paeonia lactiflora root extract has the effect of improving the aging of the dermis.
Example 3
Skin product
Toner
| Name of raw materials | Content (wt%) |
| Water (W) | To 100 |
| Radix Paeoniae extract | 0.05 |
| Panthenol | 1 |
| 1, 3-propanediol | 3 |
| 1, 2-hexanediol | 0.3 |
| Octanoyl hydroximic acid | 0.2 |
| Glycerol | 5 |
| PPG-26-Butaneth-26 | 0.2 |
| PEG-40 hydrogenated Castor oil | 0.3 |
| Essence | 0.05 |
| Hyaluronic acid | 0.1 |
Essence of plant
Face cream
The foregoing is merely a preferred embodiment of the invention and is not intended to limit the scope of the invention, which is defined by the claims appended hereto, and any other technical entity or method that is encompassed by the claims as broadly defined herein, or equivalent variations thereof, is contemplated as being encompassed by the claims.
Claims (13)
1. An application of radix Paeoniae extract in preparing composition for promoting skin cuticle exfoliation is provided.
2. An application of radix Paeoniae extract in preparing composition for promoting regeneration of epidermal layer of skin is provided.
3. An application of radix Paeoniae extract in preparing composition for resisting skin aging is provided.
4. The use of claim 3, wherein said anti-skin aging comprises promoting collagen production in the dermal layer of the skin.
5. The use of any one of claims 1-4, comprising 0.01-100 wt% of the extract of Paeonia lactiflora pall, based on the total weight of the composition.
6. The use according to claim 4, wherein the collagen is type I collagen.
7. The use of claim 5, wherein the composition is a dermatological product.
8. The use of claim 5, wherein the composition comprises an extract of paeonia lactiflora and a cosmetically acceptable carrier.
9. The use according to claim 7, wherein the product form is selected from the group consisting of a solution, a gel, a cream, a liniment, a microemulsion spray, a suspension or an emulsion.
10. The use of any one of claims 1-4, wherein the concentration of the paeonia lactiflora extract is 0.001-5 wt%, based on the total weight of the composition.
11. Use of radix Paeoniae extract in preparing composition for resisting skin aging and/or promoting skin regeneration is provided.
12. A method for promoting expression of KLK5 and/or KLK7 in keratinocytes in vitro, comprising the steps of: mixing keratinocyte with radix Paeoniae extract.
13. A method for promoting collagen i production in dermal fibroblasts in vitro, comprising the steps of: mixing fibroblast with radix Paeoniae extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111439984.XA CN114010563A (en) | 2021-11-30 | 2021-11-30 | Component with brightening and anti-aging effects and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111439984.XA CN114010563A (en) | 2021-11-30 | 2021-11-30 | Component with brightening and anti-aging effects and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114010563A true CN114010563A (en) | 2022-02-08 |
Family
ID=80067611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111439984.XA Pending CN114010563A (en) | 2021-11-30 | 2021-11-30 | Component with brightening and anti-aging effects and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114010563A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060024300A (en) * | 2004-09-13 | 2006-03-16 | 박상도 | Extraction Method of Anti-Aging Components from Red Ginseng Extract |
| CN1984637A (en) * | 2004-05-10 | 2007-06-20 | 株式会社Lg生活健康 | Skin aging treatment comprising paeoniflorin |
| JP2008094739A (en) * | 2006-10-10 | 2008-04-24 | Ogawa & Co Ltd | Skin texture ameliorant and external preparation, cosmetic, bath medicine and detergent containing the skin texture ameliorant |
| JP2008105983A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
| CN109260140A (en) * | 2018-11-22 | 2019-01-25 | 广州诗蒂兰化妆品有限公司 | A kind of marine organisms brilliant white anti-aging smoothing toner |
| CN111904906A (en) * | 2020-08-05 | 2020-11-10 | 兰研(上海)生物科技有限公司 | Composition for repairing skin barrier and improving skin resistance and preparation method thereof |
| CN112807254A (en) * | 2020-03-23 | 2021-05-18 | 上海铮信生物科技有限公司 | Skin repair composition and application thereof in cosmetics |
| CN113616565A (en) * | 2021-07-30 | 2021-11-09 | 云南白药集团上海科技有限公司 | Paeonia lactiflora root extract, skin external preparation containing same, and preparation method and application thereof |
-
2021
- 2021-11-30 CN CN202111439984.XA patent/CN114010563A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1984637A (en) * | 2004-05-10 | 2007-06-20 | 株式会社Lg生活健康 | Skin aging treatment comprising paeoniflorin |
| KR20060024300A (en) * | 2004-09-13 | 2006-03-16 | 박상도 | Extraction Method of Anti-Aging Components from Red Ginseng Extract |
| JP2008094739A (en) * | 2006-10-10 | 2008-04-24 | Ogawa & Co Ltd | Skin texture ameliorant and external preparation, cosmetic, bath medicine and detergent containing the skin texture ameliorant |
| JP2008105983A (en) * | 2006-10-25 | 2008-05-08 | Nicca Chemical Co Ltd | Fibroblast proliferation promoter, skin care preparation for external use, bathing agent, and food and drink |
| CN109260140A (en) * | 2018-11-22 | 2019-01-25 | 广州诗蒂兰化妆品有限公司 | A kind of marine organisms brilliant white anti-aging smoothing toner |
| CN112807254A (en) * | 2020-03-23 | 2021-05-18 | 上海铮信生物科技有限公司 | Skin repair composition and application thereof in cosmetics |
| CN111904906A (en) * | 2020-08-05 | 2020-11-10 | 兰研(上海)生物科技有限公司 | Composition for repairing skin barrier and improving skin resistance and preparation method thereof |
| CN113616565A (en) * | 2021-07-30 | 2021-11-09 | 云南白药集团上海科技有限公司 | Paeonia lactiflora root extract, skin external preparation containing same, and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨汝斌;万屏;刘玲;: "植物提取物抗光老化研究进展" * |
| 陆俊捷;李国娜;张成波;沈云辉;: "白芍总苷对皮肤机械屏障障碍小鼠皮肤屏障功能的影响" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110731924B (en) | Enhanced anti-aging cosmetic compositions | |
| JP6054858B2 (en) | HAS2-stimulating plant extract | |
| US20060204471A1 (en) | Compositions and regime/regimen for treating the adverse signs of cutaneous skin aging | |
| JPH09255547A (en) | Skin preparation for external use | |
| CN111973647A (en) | Preparation method of honeysuckle flower fermentation product and application of honeysuckle flower fermentation product in improving skin appearance and resisting aging | |
| JP2008105984A (en) | Collagen production promoter, skin care preparation for external use, bathing agent, and food and drink | |
| CN112656731A (en) | Composition with red-repairing effect and preparation method and application thereof | |
| CN114010563A (en) | Component with brightening and anti-aging effects and application thereof | |
| US20200164037A1 (en) | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth | |
| CN113081878B (en) | Combination for synergistically promoting synthesis of hyaluronic acid in skin and application thereof | |
| CN113317998A (en) | Anti-aging component for promoting collagen circulation and application thereof | |
| KR20180101125A (en) | Cosmetic composition for skin whitening and improving skin wrinkle comprising horse oil and Rumex acetosella L. extracts | |
| CN112618422A (en) | Composite whitening composition, preparation method and application | |
| CN113143782B (en) | Cosmetic composition for improving epidermal aging and application thereof | |
| CN111939182A (en) | Application of ginkgo callus extract and method for culturing ginkgo callus | |
| CN112675063A (en) | Skin-tendering anti-wrinkle composition containing PDRN and application thereof | |
| KR101640735B1 (en) | Composition for improving skin wrinkle | |
| JP5690495B2 (en) | Aquaporin 3 production promoter and cosmetics containing the same | |
| TW202027724A (en) | Use of extract of victoria cruziana for inducing expression of keratin gene and hyaluronan synthase 2 gene, and enhancing moisture-retaining capacity of skin | |
| KR101640736B1 (en) | Composition for improving skin wrinkle | |
| CN114028296A (en) | Multi-dimensional skin sensitivity repairing cosmetic component and application | |
| US20220105024A1 (en) | Intense Skin Hydration Systems and Methods | |
| CN117257698A (en) | Composition for improving dermis thickness, anti-aging cosmetic and preparation method thereof | |
| KR20060094704A (en) | Scalp care cosmetic composition | |
| JP6161953B2 (en) | Hair restorer, muscle activator and energy production promoter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |